XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer

NCT ID: NCT00215722

Last Updated: 2007-04-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-07-31
• Study Completion Date: 2008-07-31

Brief Summary

The first phase II trial with cetuximab and FOLFOX, as 1st line therapy for MCRC, presented at ASCO 2004, showed a 81% response rate, with no unexpected toxicities for the combination.

This study is aimed at establishing the efficacy and safety of the combination cetuximab/XELOX as first line therapy in patients with MCRC.

Detailed Description

The phase II trials with XELOX, demonstrated that is a highly effective first-line treatment for metastatic colorectal cancer, with response rates similar to the regimens with oxaliplatin and infusional 5-FU/LV (FOLFOX), but more convenient and likely to be preferred by both patients and health care providers.

Cetuximab has a significant anti-cancer activity in the setting of chemo-resistant disease which suggests that a much greater degree of benefit may ensue when it is used at an earlier stage of the disease course.

The first phase II trial with cetuximab and FOLFOX, as 1st line therapy for MCRC, presented at ASCO 2004, showed a 81% response rate, with no unexpected toxicities for the combination.

This study is aimed at establishing the efficacy and safety of the combination cetuximab/XELOX as first line therapy in patients with MCRC.

Conditions

Colorectal Carcinoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Cetuximab

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Signed written informed consent, prior any study-specific procedures
• Male or female > = 18 years of age
• Histologically confirmed adenocarcinoma of the colon or rectum with metastatic disease not eligible for surgery with curative intent - in case of a unique metastatic lesion this should be confirmed by biopsy
• ECOG performance status < 1 at study entry
• Immunohistochemical evidence of EGFR expression on tumour tissue
• Presence of at least one unidimensional measurable lesion with a diameter > 20mm by conventional CT scan or MRI, and 10mm by spiral CT scan, according to the RECIST criteria (Index lesion(s) must not lie within an irradiated area)
• Have not received any Chemotherapy regimen for metastatic disease
• Life expectancy of > 3 months
• Neutrophils > = 1.5 x 109/L, platelet count > = 100 x 109/L, and haemoglobin > = 9 g/dL.
• Bilirubin level either normal or 1.5 x ULN
• ASAT and ALAT < = 2.5 x ULN (< = 5 x ULN in case of liver metastasis)
• Alkaline phosphatase < = 2.5 x ULN or < = 5 x ULN in case of liver metastasis or < = 10 x ULN in case of bone metastases
• Serum creatinine < = 1.5 x ULN or CrCl > 50 ml/min (Cockroft and Gault formula)
• Negative Pregnancy test within one week before treatment start, if applicable

Exclusion Criteria

• Previous chemotherapy for metastatic CRC or adjuvant therapy with oxaliplatin or irinotecan.
• Adjuvant or neo-adjuvant therapy with 5 FU or derivatives is allowed if the chemotherapy treatment free interval is > 6 months and the patient have not progressed during treatment
• Surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to study entry
• Prior radiotherapy is permitted if it was not administered to target lesions selected for this study
• Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not indicated in the study protocol
• Any investigational agent(s) within 4 weeks prior to entry
• Previous exposure to EGFR-pathway targeting therapy
• History of evidence upon physical examination of CNS disease (e.g. primary brain tumour, seizure not controlled with standard therapy, any brain metastasis or history of stroke)
• Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months
• Serious uncontrolled intercurrent infections, or other serious uncontrolled concomitant disease
• Acute or subacute intestinal occlusion or history of inflammatory bowel disease
• Pre-existing neuropathy > grade 1
• Known grade 3 or 4 allergic reaction to any of the components of the treatment.
• Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix. (Patients with a previous malignancy but without evidence of disease for > = 5 years will be allowed to enter the trial)
• Known drug abuse/ alcohol abuse
• Legal incapacity or limited legal capacity
• Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent
• Pregnant or lactating women
• Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study
• Lack of physical integrity of the upper gastrointestinal tract or those who have malabsorption syndrome
• Known dihydropyrimidine dehydrogenase deficiency

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Grupo de Investigacao do Cancro Digestivo

OTHER

Sponsor Role: lead

Principal Investigators

Evaristo Sanches, MD

Role: PRINCIPAL_INVESTIGATOR

Grupo de Investigação do Cancro Digestivo

Sérgio Barroso, MD

Role: PRINCIPAL_INVESTIGATOR

Grupo de Investigação do Cancro Digestivo

Locations

Hospital Garcia de Orta

Almada, , Portugal

Hospital Distrital do Barreiro

Barreiro, , Portugal

Hospital Distrital de Beja

Beja, , Portugal

Hospital de São Marcos

Braga, , Portugal

Hospitais da Universidade de Coimbra

Coimbra, , Portugal

IPO - Coimbra

Coimbra, , Portugal

Centro Hospitalar do Funchal

Funchal, , Portugal

Hospital Pedro Hispano

Matosinhos Municipality, , Portugal

Hospital do Divino Espírito Santo

Ponta Delgada, , Portugal

IPO - Porto

Porto, , Portugal

Countries

Portugal

Other Identifiers

GICR-P003

Identifier Type: -

Identifier Source: org_study_id